Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

× No keyword cloud information.

19 in total

1. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

Authors: Su-bo Qian; Hai-bo Shen; Qi-feng Cao; Lin Zhang; Yi-fan Chen; Jun Qi
Journal: Int Urol Nephrol Date: 2015-02-10 Impact factor: 2.370

Review 2. The changing therapeutic landscape of castration-resistant prostate cancer.

Authors: Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal: Nat Rev Clin Oncol Date: 2011-08-09 Impact factor: 66.675

Review 3. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors: David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal: Nat Rev Urol Date: 2015-01 Impact factor: 14.432

Review 4. Mechanisms of androgen receptor activation in castration-resistant prostate cancer.

Authors: Nima Sharifi
Journal: Endocrinology Date: 2013-09-03 Impact factor: 4.736

Review 5. An update on androgen deprivation therapy for prostate cancer.

Authors: Nima Sharifi; James L Gulley; William L Dahut
Journal: Endocr Relat Cancer Date: 2010-10-29 Impact factor: 5.678

6. Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.

Authors: Andrew J Cowan; Yoshio Inoue; Evan Y Yu
Journal: Clin Genitourin Cancer Date: 2014-09-22 Impact factor: 2.872

Review 7. Antiandrogens in prostate cancer.

Authors: P Reid; P Kantoff; W Oh
Journal: Invest New Drugs Date: 1999 Impact factor: 3.850

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.